• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • SPORE In Prostate Cancer
    • External Funding Opportunities
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. Active Surveillance for Cancer of the Prostate (ASCAP)

Active Surveillance for Cancer of the Prostate (ASCAP)

Share this

Active Surveillance for Cancer of the Prostate (ASCAP): An Observational Study to Help Us Monitor and Learn More About Prostate Cancer

Technical Title: Active Surveillance for Cancer of the Prostate (ASCAP)

Disease Type: Low risk prostate cancer

Basic information:
This observational study looks at patients with evidence of "low-risk" prostate cancer that does not require immediate treatment.  Many men found to have prostate cancer have such a small amount of tumor that any future growth or spread is unlikely. This study helps researchers learn more about the natural history and factors leading to progression or stabilization of these small prostate tumors.  In this program, patients are followed indefinitely, until they elect to withdraw, or are advised by the researchers that they need to seek prostate cancer treatment.

Research Procedures (not a complete list):
Patients will be invited to participate in this study after evidence of low-risk prostate cancer is diagnosed following prostate biopsy. Patients who enroll will be asked annually to participate in optional questionnaires to collect quality-of-life data and optional blood draws for future biomarker testing. Follow-up assessments, such as PSA blood draw and prostate exam, will be done every 6 months according to conventional care standards. MRI-targeted fusion biopsies will be performed as deemed necessary by a health care provider.

Eligibility Criteria (not a complete list):
Inclusion Criteria:

  • Diagnosis of clinically localized (T1 to T2) prostate cancer
  • Patient elects active surveillance as preferred management plan for prostate cancer

Exclusion Criteria:

  • Patient is unwilling to undergo prostate biopsy

For More Detailed Information, Contact:

  • Leonard Marks, MD, Principal Investigator, Professor of UCLA Urology
  • Merdie Delfin, NP, Study Coordinator

Read more about this study (NCT00949819) on ClinicalTrials.gov.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest